Advertisement

Picture Berlin Partner German Biotech Days 2024 in Berlin 650x100px
Document › Details

Bayer AG. (6/5/23). "Press Release: Bayer Strengthens Gene Therapy Portfolio with Lipid Nanoparticle Technology from Acuitas Therapeutics [Not intended for U.S. and UK Media]". Berlin.

Organisations Organisation Asklepios BioPharmaceutical Inc. (AskBio)
  Group Bayer (Group)
  Organisation 2 Acuitas Therapeutics Inc.
Products Product lipid nanoparticle technology (LNP technology)
  Product 2 RNA-based therapeutic
Index term Index term Bayer–Acuitas Therapeutics: LNP technology, 202306– collab €na using LNP technology to deliver RNA payloads to liver
Persons Person Janus, Friedemann (Bayer 202306 acting Head of Business Development + Licewnsing/Open Innvation for Pharma Div)
  Person 2 Madden, Thomas (Tom) (Acuitas Therapeutics 202306 CEO)
     


   
Record changed: 2024-01-20

Advertisement

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

More documents for Bayer (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner German Biotech Days 2024 in Berlin 650x300px




» top